The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility
Abstract
The first recorded report describing evidence for an AR originates from 1976. Now, 30 years later, advances in understanding the role of adenosine and its receptors in physiology and pathophysiology as well as new developments in medicinal chemistry of these receptors have enabled researchers to identify potential therapeutic areas for drug development. With the combination of pharmacological data, using selective ligands and genetically modified mice, important progress has been made toward an understanding of the role of ARs in a variety of diseases, such as inflammatory conditions, sepsis, heart attack, ischemia-reperfusion injury, vascular injury, spinal cord injury, chronic obstructive pulmonary disease (COPD), asthma, diabetes, obesity, inflammatory bowel disease, retinopathy, and Parkinson’s Disease (PD). Nonselective AR antagonists are used to maintain wakefulness (caffeine) and, less commonly at present, treat bronchospasm (theophylline, aminophylline, enprofylline). Currently a number of new selective AR agonists and antagonists are in testing for a variety of new indications. Therefore, the purpose of this review is to analyze the structure-activity relationships of the ligands synthesized as antagonists for the ARs. We have included some synthetic schemes in order to show the chemistry involved in this field. In particular, we will investigate antagonists under active development that selectively target the four known AR subtypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Cited by
Immune cell regulation by autocrine purinergic signalling
Junger, W. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri2938 · Cited by 810
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Self-citationChromone: A Valid Scaffold in Medicinal Chemistry
Gaspar, A., Matos, M. J., Garrido, J., Uriarte, E., & Borges, F. (2014) · Chemical Reviews · doi:10.1021/cr400265z · Cited by 760
Recent developments in adenosine receptor ligands and their potential as novel drugs
Müller, C. E., & Jacobson, K. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.017 · Cited by 431
Disulfide- and Multisulfide-Containing Metabolites from Marine Organisms
Jiang, C.-S., Müller, W. E. G., Schröder, H. C., & Guo, Y.-W. (2012) · Chemical Reviews · doi:10.1021/cr200173z · Cited by 294
Adenosine A 2A Receptor as a Drug Discovery Target
de Lera Ruiz, M., Lim, Y.-H., & Zheng, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4011669 · Cited by 276
Caffeine and cardiovascular health
Turnbull, D., Rodricks, J. V., Mariano, G. F., & Chowdhury, F. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.07.025 · Cited by 216
Metadata
- Authors
- Baraldi, P. G., Tabrizi, M. A., Gessi, S., & Borea, P. A.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-01-01
- Volume
- 108
- Issue
- 1
- Pages
- 238-263
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2094515040
- Cited by
- 238
- References
- 3
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.